Ownership history in UBS Group AG Β· 8 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in PROMIS NEUROSCIENCES INC (PMN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π UBS Group AG underperformed the S&P 500 by β145.2% annually on this PMN position. Timing score: 71% (5/7 decisions correct). Average cost basis: $58.04. Maximum drawdown during holding period: β95.5%.
β Significantly underperformed the S&P 500 by 145.2% ann.
7 quarters analyzed
π― Smart timing β consistently buying dips and trimming near peaks.
5 of 7 add/trim decisions correct
Best entry: $10.75 (2025 Q3) Β· Worst: $153.25 (2022 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 5 trims. Bought during 2 of 6 down-price quarters. π Predominantly trimming β distribution phase.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size